Immunogenicity and Efficacy of Subcutaneous Infliximab Monotherapy vs Combination Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
Open Access
- 14 May 2025
- journal article
- review article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 24 (1) , 57-68.e5
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY)Gastroenterology, 2024
- EFFICACY, SAFETY AND IMMUNOGENICITY OF SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) MONOTHERAPY VERSUS COMBINATION THERAPY WITH IMMUNOSUPPRESSANTS – POST HOC ANALYSIS OF LIBERTY-CD AND LIBERTY-UC STUDYGastroenterology, 2024
- Subcutaneous Infliximab Monotherapy Versus Combination Therapy with Immunosuppressants in Inflammatory Bowel Disease: A Post Hoc Analysis of a Randomised Clinical TrialClinical Drug Investigation, 2023
- Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH StudyClinical Gastroenterology and Hepatology, 2022
- Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel DiseaseGastroenterology, 2021
- Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort studyThe Lancet Gastroenterology & Hepatology, 2019
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative ColitisGastroenterology, 2014
- Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled TrialsClinical Gastroenterology and Hepatology, 2008
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002
- A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's DiseaseNew England Journal of Medicine, 1997